Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

[Tester av enhet som inte är godkänd eller godkänd av U.S. FDA] (PIERRE)

5 november 2026 uppdaterad av: Alcyone Therapeutics, Inc

The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).

All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Detaljerad beskrivning

This is a multicenter, multi-national, prospective, non-randomized, single arm, group sequential design, pivotal clinical investigation (device exemption study) to assess the safety and performance of the ThecaFlex DRx™ System in subjects with SMA.

The subject population will include subjects aged ≥ 3 years with SMA who are considered candidates for intrathecal port and catheter implantation because they require chronic, bolus intrathecal administration of necessary therapy, and who meet all the inclusion/exclusion criteria for the clinical investigation.

After a screening period of up to 200 days, all enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant.

In agreement with the nusinersen dosing information, the treatment frequency will be adapted for non-naïve and naïve subjects:

Subjects who are not naïve to nusinersen should have nusinersen maintenance doses administered via the implant every 4 months (i.e., 4, 8, and 12 months after their last nusinersen dose, before enrollment in the clinical investigation).

Subjects who are naïve to nusinersen will have their loading and maintenance doses administered via the device according to the drug labeling.

A DMC and Clinical Events Committee (CEC), independent of each other and the Sponsor, will be used to perform ongoing consistent adjudication of events related to the safety throughout the entire duration of the clinical investigation and to periodically review data that relate to the safety of the study.

The clinical investigation will enroll 90 subjects. The clinical investigation incorporates a lead-in phase which consists of 10 subjects enrolled, implanted, and followed for 30-days. Enrollment for the lead-in phase is expected to take approximately 6 to 9 months, at which point the Data Monitoring Committee (DMC) will review the data for safety and approve continuation of enrollment. The second phase of enrollment is expected to take approximately 12 to 15 months.

Individual subjects are anticipated to be enrolled in the clinical investigation for approximately 37 months. The total duration of this clinical investigation is estimated to be approximately 60 months.

Studietyp

Interventionell

Inskrivning (Beräknad)

90

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85013
    • California
      • Orange, California, Förenta staterna, 92868
      • Palo Alto, California, Förenta staterna, 94301
      • San Diego, California, Förenta staterna, 92037
    • Florida
      • Orlando, Florida, Förenta staterna, 32827
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Har inte rekryterat ännu
        • John's Hopkins Children's Center
        • Huvudutredare:
          • Thomas Crawford, MD
        • Kontakt:
    • Massachusetts
    • Michigan
    • New York
      • New York, New York, Förenta staterna, 10032
        • Rekrytering
        • Columbia University Irving Medical Center/NewYork Presbyterian Hospital
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
    • Pennsylvania
      • Hershey, Pennsylvania, Förenta staterna, 17033
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Rekrytering
        • Children's Hospital Philadelphia
        • Kontakt:
    • Texas
      • Austin, Texas, Förenta staterna, 78723
        • Har inte rekryterat ännu
        • Dell Children's Medical Center of Central Texas
        • Kontakt:
        • Huvudutredare:
          • Vettaikorumakankav Vedanarayanan, MD
      • Houston, Texas, Förenta staterna, 77030
    • Virginia
      • Charlottesville, Virginia, Förenta staterna, 22903
        • Rekrytering
        • University of Virginia
        • Kontakt:
          • Chelsea Masterson
        • Kontakt:
      • Norfolk, Virginia, Förenta staterna, 23510
      • Sheffield, Storbritannien
        • Rekrytering
        • Sheffield Teaching Hospitals NHS Foundation Trust
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

3 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Subject is 3 years or older

  2. Subject is diagnosed with SMA and is a candidate for Spinraza treatment as indicated in country-specific label

  3. Subject resistant to lumbar puncture (LP), where resistance is defined as:

    1. Subject with respiratory issues or other comorbidities who is at an increased risk for complications due to the need for repeat anesthesia and imaging radiation exposure to safely perform LP; or
    2. Subjects for whom the treating physician determines implantation of the ThecaFlex DRx™ System is otherwise in the subject's best interest
  4. Subject has been prescribed nusinersen via chronic intrathecal bolus administration in accordance with the country-specific drug labeling

  5. Subject, per Investigator discretion, is able to undergo a percutaneous or open surgical procedure for index port and catheter implantation where at least 7 cm of the ThecaFlex DRx system catheter will be placed intrathecally

  6. Subject (or subject's legally authorized representative) is willing and able to provide written informed consent; and

  7. Subject and parent/caregiver able and willing to complete all clinical investigation procedures, measurements, and visits.

Exclusion Criteria:

  1. Subject meets any of the contraindications for use of the ThecaFlex DRx System as outlined in the ThecaFlex DRx System Instructions for Use

  2. Presence or history of (< 6 months prior to the procedure): an implanted microinfusion pump, intrathecal catheter, or other intrathecal drug delivery devices/component, or implanted shunt for drainage of cerebrospinal fluid (CSF), or reservoir in the CSF space (note: any ThecaFlex Port and Catheter System must not be placed in the same location as a previous indwelling port and catheter)

  3. Subject is pregnant or nursing or plans to become pregnant during the course of the clinical investigation, or is a woman of childbearing potential or a man of reproductive age who is unwilling or unable to practice contraception, as described in Section 14.10.

  4. Any condition or event, which in the opinion of the Investigator may adversely affect the safety and effective implantation and use of the ThecaFlex DRx system or confound the clinical investigation, including:

    1. Severe structural impediment that may preclude safe implantation of the catheter and port
    2. Major medical events (as defined per investigator's discretion) within 60 days prior to screening; or
    3. Relevant surgeries (e.g., head and neck, back, etc.) within 60 days prior to screening or planned during the duration of the clinical investigation
    4. Space-occupying lesion with mass effect
    5. Posterior fossa mass
    6. Arnold-Chiari malformation
    7. Coagulation abnormalities and/or thrombocytopenia
    8. Insufficient or inadequate skin or underlying fat to adequately protect the port or enough surface area to allow the skin to close safely
  5. Subject is contraindicated for administration of nusinersen per its approved country-specific labeling

  6. History of intrathecal granuloma formation

  7. History of bacterial meningitis or aseptic meningitis within 6 months of screening

  8. History of tumors or other spinal abnormalities documented by magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with the catheter implantation procedures or CSF circulation

  9. History of hydrocephalus

  10. Diagnosed degenerative muscular disease other than SMA

  11. History of depression, cognitive impairment, or another psycho-behavioral problem that in the opinion of the Investigator may preclude safe participation in the clinical investigation and

  12. Serious medical condition that, in the opinion of the investigator, may lead to reduced life expectancy beyond 12 months.

  13. Subject is involved in another Investigation Device Exemption Study.

  14. Subject has clinically meaningful immunosuppression, in the opinion of the investigator, either from therapy or a comorbid condition, which, in the opinion of the investigator, makes them a poor surgical candidate due to increased risk of infection.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: ThecaFlex DRx Port and Catheter System

Subjects who meet all of the inclusion and none of the exclusion would be eligible to receive the ThecaFlex DRx Port and Catheter System.

The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Andelen försökspersoner med framgångsrik(a) intratekal terapiinfusion under 12 månader
Tidsram: 12 månader
12 månader
The proportion of subjects with successful Implantation of the ThecaFlex DRx™ Port and Catheter
Tidsram: 12 Months

The primary outcome measures the proportion of subjects with successful implantation of the ThecaFlex DRx™ Port and Catheter System who are able to receive successful intrathecal therapy infusion(s).

12 Months

Sekundära resultatmått

Resultatmått
Tidsram
Andel försökspersoner med minskad anestesi och strålningsexponering jämfört med upprepad LP för nusinersen-infusion hos SMA-personer.
Tidsram: 12 månader
12 månader
Incidensen av enhetsrelaterade biverkningar (AE)/komplikationer under 12 månader
Tidsram: 12 månader
12 månader
Förekomst av procedurkomplikationer under 12 månader
Tidsram: 12 månader
12 månader
Förekomst av nusinersen-relaterade biverkningar
Tidsram: 12 månader
12 månader
Genomsnittlig varaktighet för strålningsexponering från implantat till 12 månaders uppföljning
Tidsram: 12 månader
12 månader

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

27 november 2023

Primärt slutförande (Beräknad)

1 april 2028

Avslutad studie (Beräknad)

1 juli 2030

Studieregistreringsdatum

Först inskickad

10 maj 2023

Först inskickad som uppfyllde QC-kriterierna

10 maj 2023

Första postat (Faktisk)

19 maj 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera